UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1329-6
Program Prior Authorization/Notification
Medication Zolinza® (vorinostat)
P&T Approval Date 9/2020, 9/2021, 10/2021, 10/2022, 10/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Zolinza® (vorinostat) is a histone deacetylase (HDAC) inhibitor indicated for the treatment of
cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have
progressive, persistent, or recurrent disease on or following two systemic therapies. The National
Cancer Comprehensive Network (NCCN) also recommends the use of Zolinza as a systemic
therapy as primary treatment or subsequent for cutaneous T-cell lymphoma (CTCL).
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the notification
criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Zolinza will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Cutaneous T-cell Lymphoma (CTCL)
1. Initial Authorization
a. Zolinza will be approved based on the following criteria:
(1) Diagnosis of cutaneous T-cell Lymphoma (CTCL)
-AND-
(2) Patient has progressive, persistent, or recurrent disease on or following two
systemic therapies [e.g., Adcetris (brentuximab vedotin), bexarotene, interferon
alfa-db, interferon gamma-1b, methotrexate, Poteligeo (mogamulizumab),
© 2024 UnitedHealthcare Services, Inc.
1
romidepsin]
Authorization will be issued for 12 months.
2. Reauthorization
a. Zolinza will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Zolinza therapy
Authorization will be issued for 12 months.
C. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Zolinza [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; July 2022.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
http://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed
August 29, 2024.
Program Prior Authorization/Notification – Zolinza® (vorinostat)
Change Control
9/2020 New program.
9/2021 Annual review with no changes to coverage criteria. Updated
references.
10/2021 Updated criteria to align with label. Updated references.
10/2022 Annual review with no changes to coverage criteria. Added state
mandate footnote. Updated references.
10/2023 Annual review with no changes to coverage criteria. Updated
© 2024 UnitedHealthcare Services, Inc.
2
references.
10/2024 Annual review with no changes to coverage criteria. Updated
background and references.
© 2024 UnitedHealthcare Services, Inc.
3